Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK1 | P57059 | 1/20 | 1.00 |
| ▸ | MELK | Q14680 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 1.00 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 8/20 | 0.62 |
| ▸ | SRC | P12931 | 3/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15271960 | 1.00 | SIK1 (1.00) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL17537405 | 0.95 | SIK1 (0.90) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL17509519 | 0.92 | SIK1 (0.85) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL19224077 | 0.92 | SIK1 (0.85) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL19224078 | 0.92 | SIK1 (0.85) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL21337898 | 0.91 | SIK1 (0.84) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL17537393 | 0.91 | SIK1 (0.84) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL17537394 | 0.90 | SIK1 (0.82) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL19224070 | 0.90 | SIK1 (0.82) | SIK1MELKSIK2SIK3LCK | |
| SCHEMBL17537407 | 0.89 | SIK1 (0.81) | SIK1MELKSIK2SIK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118546871-B | Method for differentiating human pluripotent stem cells into mesenchymal stem cells | 未来智人再生医学研究院(广州)有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119074735-A | Application of compound HG9-91-01, dabrafenib, AZD5423, GSK840 or HS-1371 in preparation of medicine for preventing and treating retinal hypoxia-ischemic injury | 广州国家实验室 | 2024-12-06 | — | — | CN | claimed |
| CN-118546871-A | Method for differentiating human pluripotent stem cells into mesenchymal stem cells | 未来智人再生医学研究院(广州)有限公司 | 2024-08-27 | — | — | CN | claimed |
| US-11690897-B2 | Salt inducible kinase inhibitors for enhancing fertility | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | claimed |
| CN-114948860-B | Supermolecule hydrogel nano material, gel factor, preparation method and application thereof | 东南大学 | 2023-04-28 | — | — | CN | claimed |
| CN-114948860-A | Supermolecule hydrogel nano material, gelator, preparation method and application thereof | 东南大学 | 2022-08-30 | — | — | CN | claimed |
| EP-4737443-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20260078126-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4047001-A2 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | The Broad Institute, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220202827-A1 | Enhancement of Melanocyte Migration Using ROCK Inhibitors | THE GENERAL HOSPITAL CORPORATION | 2022-06-30 | — | — | US | disclosed |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3982922-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | Technical University of Denmark (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-11285144-B2 | Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity | THE BROAD INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11285158-B2 | Uses of pyrimidopyrimidinones as SIK inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2022-03-29 | — | — | US | disclosed |
| CN-114159568-A | Use of SIK inhibitors for the preparation of a medicament for the prevention and/or treatment of sleep disorders | 北京原基华毅生物科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SIK1, SIK3, SIK2 | SIK1 1/4885MELK 328/4885SIK2 3/4885 |
| US-20260078126-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK2, SBK3, SIK3 | SIK1 5/4885MELK 511/4885SIK2 1/4885 |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | SIK1 2/4885MELK 162/4885SIK2 1/4885 |
| US-11285144-B2 | Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity | CDK8, CDK9, CDK6 | SIK1 804/4885MELK 1483/4885SIK2 1597/4885 |
| US-11690897-B2 | Salt inducible kinase inhibitors for enhancing fertility | SGK2, SGK1, MAPKAPK2 | SIK1 37/4885MELK 45/4885SIK2 12/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | SIK1 4678/4885MELK 3770/4885SIK2 4608/4885 |
| US-11285158-B2 | Uses of pyrimidopyrimidinones as SIK inhibitors | SIK2, SIK1, SIK3 | SIK1 2/4885MELK 162/4885SIK2 1/4885 |
| US-20250340886-A1 | INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF | SIK3, SIK1, SIK2 | SIK1 2/4885MELK 339/4885SIK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.